Ranbaxy’s Private-Label Loratadine OTCs Spared By FDA Probe
This article was originally published in The Tan Sheet
Several first-to-file abbreviated new drug applications are on the line as Ranbaxy tries to resolve data integrity issues with FDA concerning its Paonta Sahib, India, facility
You may also be interested in...
India's largest drug maker, Ranbaxy, faces a hurdle to growing its U.S. business with FDA's ban on imports of some of its products, including an OTC drug
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.